Financial disclosure requirements under 21 CFR Part 54: the RC's coordination role
Analyzes 21 CFR Part 54 financial disclosure requirements from the RC's coordination perspective, designs portfolio-level tracking systems for multi-study investigators, and evaluates the complexity of financial disclosure when investigators hold roles across multiple sponsors.
The regulation nobody reads until it matters
I have a confession to make. In 30 years of teaching clinical research, 21 CFR Part 54 is the regulation I find most difficult to make interesting in a classroom setting. It does not have the narrative urgency of informed consent. It does not have the operational immediacy of a clinical hold. It is a disclosure regulation -- about money, about forms, about annual re-certification.
And yet. In the past decade, I have seen more audit findings related to financial disclosure than to almost any other category of regulatory requirement at investigator sites. Not because the rules are complex -- they are, in fact, relatively straightforward. But because the coordination required to keep disclosures current, across multiple investigators, across multiple studies, across multiple sponsors with different collection schedules and different form requirements, is a portfolio-level challenge that many sites manage reactively rather than systematically.
This lesson is not about what 21 CFR Part 54 requires. The CRC track covered the regulation itself. This lesson is about how the RC coordinates the disclosure process across the portfolio -- the tracking systems, the annual cycles, the operational reality of collecting sensitive financial information from investigators who would rather not discuss it.
What you will learn
By the end of this lesson, you will be able to: